Clinical trial
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients…
NCT00060502 · Centocor, Inc., Industry · Completed
Key facts
| NCT number | NCT00060502 |
|---|---|
| Title | A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia |
| Official title | A Phase II, Multicenter, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Anti-TNF a Monoclonal Antibody (Infliximab) to Treat Cancer-Related Cachexia in Subjects With Pancreatic Cancer. |
| Lead sponsor | Centocor, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cachexia, Pancreatic Neoplasms |
| Intervention type | Drug |
| Interventions | Infliximab, Gemcitabine |
| Enrollment | 73 |
| Start date | Apr 1, 2003 |
| Completion | Feb 1, 2006 |
| First posted | May 8, 2003 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: